Tech Company Financing Transactions

Pearl Therapeutics Funding Round

Pearl Therapeutics secured a $65 million Series D financing round on 11/13/2012. Investors included Vatera Healthcare Partners, 5AM Ventures and Clarus.

Transaction Overview

Company Name
Pearl Therapeutics
Announced On
11/13/2012
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series D
Investors

Vatera Healthcare Partners (Lead Investor) (Sundar Kodiayalam)

5AM Ventures (James Young)

Clarus (Nicholas Simon)

New Leaf Venture Partners (Kathleen LaPorte)

Proceeds Purpose
Proceeds from this financing will be used by Pearl to start Phase 3 for PT003, Pearl's lead candidate product comprised of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI).

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
200 Saginaw Drive
Redwood City, CA 94063
USA
Phone
(650) 305-2600
Website
www.pearltherapeutics.com
Email Address
[email protected]
Overview
Pearl Therapeutics is focused on developing a pipeline of novel andsuperior products for chronic respiratory disorders, providing patientswith advanced therapeutic options in familiar and well accepted dosageforms. The company has licensed advanced particle technology from NektarTherapeutics (Nasdaq: NKTR) for developing a series of products in selectedtherapeutic fields.
Profile
Pearl Therapeutics LinkedIn Company Profile
Social Media
Pearl Therapeutics Company Twitter Account
Company News
Pearl Therapeutics News
Facebook
Pearl Therapeutics on Facebook
YouTube
Pearl Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Charles Bramlage
  Charles Bramlage LinkedIn Profile  Charles Bramlage Twitter Account  Charles Bramlage News  Charles Bramlage on Facebook
Chief Medical Officer
Colin Reisner
  Colin Reisner LinkedIn Profile  Colin Reisner Twitter Account  Colin Reisner News  Colin Reisner on Facebook
Chief Scientific Officer
Sarvajna Dwivedi
  Sarvajna Dwivedi LinkedIn Profile  Sarvajna Dwivedi Twitter Account  Sarvajna Dwivedi News  Sarvajna Dwivedi on Facebook
VP - Bus. Development
Lyn Baranowski
  Lyn Baranowski LinkedIn Profile  Lyn Baranowski Twitter Account  Lyn Baranowski News  Lyn Baranowski on Facebook
VP - Finance
William Picht
  William Picht LinkedIn Profile  William Picht Twitter Account  William Picht News  William Picht on Facebook
VP - Product Management
Robert Schultz
  Robert Schultz LinkedIn Profile  Robert Schultz Twitter Account  Robert Schultz News  Robert Schultz on Facebook
VP - Regulatory Affairs
Michael Golden
  Michael Golden LinkedIn Profile  Michael Golden Twitter Account  Michael Golden News  Michael Golden on Facebook

 

 

Browse more venture capital transactions:

Prev: 11/13/2012: 6fusion venture capital transaction
Next: 11/13/2012: MoJiva venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.